HomeCompareSMFR vs BTI

SMFR vs BTI: Dividend Comparison 2026

SMFR yields 643.92% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SMFR wins by $457922.44M in total portfolio value
10 years
SMFR
SMFR
● Live price
643.92%
Share price
$0.31
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$457922.48M
Annual income
$350,764,431,454.41
Full SMFR calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — SMFR vs BTI

📍 SMFR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSMFRBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SMFR + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SMFR pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SMFR
Annual income on $10K today (after 15% tax)
$54,732.78/yr
After 10yr DRIP, annual income (after tax)
$298,149,766,736.25/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, SMFR beats the other by $298,149,764,367.60/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SMFR + BTI for your $10,000?

SMFR: 50%BTI: 50%
100% BTI50/50100% SMFR
Portfolio after 10yr
$228961.26M
Annual income
$175,382,217,120.52/yr
Blended yield
76.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

SMFR
Analyst Ratings
2
Buy
2
Hold
Consensus: Buy
Price Target
$2.33
+650.2% upside vs current
Range: $1.00 — $3.00
Altman Z
-1.9
Piotroski
5/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SMFR buys
0
BTI buys
0
No recent congressional trades found for SMFR or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSMFRBTI
Forward yield643.92%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$457922.48M$37.7K
Annual income after 10y$350,764,431,454.41$2,786.64
Total dividends collected$449105.80M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy
Analyst price target$2.33$40.00

Year-by-year: SMFR vs BTI ($10,000, DRIP)

YearSMFR PortfolioSMFR Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$75,092$64,391.50$11,299$598.92+$63.8KSMFR
2$532,241$451,892.93$12,794$703.91+$519.4KSMFR
3$3,562,928$2,993,430.52$14,518$829.07+$3.55MSMFR
4$22,540,026$18,727,693.09$16,513$978.64+$22.52MSMFR
5$134,843,380$110,725,551.39$18,827$1,157.84+$134.82MSMFR
6$763,351,740$619,069,323.81$21,518$1,373.12+$763.33MSMFR
7$4,092,082,536$3,275,296,174.56$24,657$1,632.46+$4092.06MSMFR
8$20,787,693,434$16,409,165,120.49$28,329$1,945.74+$20787.67MSMFR
9$100,147,705,392$77,904,873,416.94$32,637$2,325.33+$100147.67MSMFR
10$457,922,476,223$350,764,431,454.41$37,708$2,786.64+$457922.44MSMFR

SMFR vs BTI: Complete Analysis 2026

SMFRStock

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.

Full SMFR Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this SMFR vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SMFR vs SCHDSMFR vs JEPISMFR vs OSMFR vs KOSMFR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.